Cite
130 (PB-130) Poster - Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients (pts) with HER2+ metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA).
MLA
Yao, H., et al. “130 (PB-130) Poster - Effective Anti-Diarrhea Strategies for Pyrotinib (PYR) plus Trastuzumab (H) and Docetaxel (T) in Patients (Pts) with HER2+ Metastatic Breast Cancer (MBC): A Multicenter, Phase 1 Trial (PHAENNA).” European Journal of Cancer, vol. 200, Mar. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejca.2024.113704.
APA
Yao, H., Shi, Y., Yao, Y., Li, H., Zhou, H., Wang, S., Qin, Q., Li, W., Geng, C., Wang, M., Wang, X., Cao, Y., Yu, Z., Du, C., Zhao, W., Wu, S., Cui, Y., Liu, P., Lin, J., & Song, E. (2024). 130 (PB-130) Poster - Effective anti-diarrhea strategies for pyrotinib (PYR) plus trastuzumab (H) and docetaxel (T) in patients (pts) with HER2+ metastatic breast cancer (mBC): a multicenter, phase 1 trial (PHAENNA). European Journal of Cancer, 200, N.PAG. https://doi.org/10.1016/j.ejca.2024.113704
Chicago
Yao, H., Y. Shi, Y. Yao, H. Li, H. Zhou, S. Wang, Q. Qin, et al. 2024. “130 (PB-130) Poster - Effective Anti-Diarrhea Strategies for Pyrotinib (PYR) plus Trastuzumab (H) and Docetaxel (T) in Patients (Pts) with HER2+ Metastatic Breast Cancer (MBC): A Multicenter, Phase 1 Trial (PHAENNA).” European Journal of Cancer 200 (March): N.PAG. doi:10.1016/j.ejca.2024.113704.